Compare Aegon Ltd. (AEG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Sanofi SA — how do they compare? Aegon Ltd. trades at $9.41 (market cap $14.01B), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 7.4× Aegon Ltd.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| AEG | SNY | |
|---|---|---|
Market Cap | $14.01B | $104.30B |
Sector | Financials | Health |
52-Week High | $9.53 | $52.34 |
52-Week Low | $6.79 | $41.33 |
Enterprise Value | $15.16B | $124.19B |
Dividend Yield | 4.94% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.45, down 0.84% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company maintains a P/E of 13.54 and P/S of 0.57, indicating potential undervaluation, while a strategic shift to U.S. focus and a $0.25 dividend highlight corporate stability.
The outlook is cautiously optimistic, supported by deleveraging trends and revenue growth projections to $26.9B in 2025. Risks include volatile cash flows and competitive pressures, but analyst consensus leans hold with 50% rating, suggesting steady performance amid transformation efforts.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
